COMP360 Phase 2 Analysis Supports Psilocybin Effects in PTSD

Compass Pathways has reported new evidence supporting the clinical model used in its investigational COMP360 synthetic psilocybin program for post-traumatic stress disorder (PTSD). A post-hoc analysis of an open-label Phase 2 trial found that patient-support interactions during dosing sessions were limited, non-directive, and substantially different from traditional psychotherapeutic interventions. The results have been published in the Journal of Psychopharmacology.

The analysis evaluated documented speech between participants and trained support providers during COMP360 administration sessions. Researchers found that approximately 78% of the treatment session occurred in silence, with support focused primarily on maintaining patient safety and providing reassurance rather than guiding or interpreting patients’ experiences.

Scientific and Clinical Context

COMP360 is a proprietary synthetic formulation of psilocybin under clinical investigation for several psychiatric disorders, including treatment-resistant depression (TRD) and PTSD. Unlike conventional psychotherapy, the treatment model incorporates structured monitoring and supportive care without therapist-led cognitive or behavioral interventions during the psychedelic experience.

PTSD is a chronic psychiatric disorder that develops after exposure to traumatic events such as combat, assault, accidents, or natural disasters. The condition affects an estimated 13 million people in the United States each year and is associated with intrusive memories, avoidance behaviors, hyperarousal, depression, anxiety, substance use disorders, and an elevated risk of suicide. Despite the substantial disease burden, only two medications have received U.S. Food and Drug Administration (FDA) approval for PTSD, highlighting the need for additional treatment options.

Phase 2 Analysis Highlights Minimal, Non-Directive Support

The post-hoc analysis examined interactions recorded during an open-label Phase 2 COMP360 study in patients with PTSD. Rather than functioning as psychotherapy, support providers primarily monitored participants and intervened only when necessary.

Key findings included

• Approximately 78% of treatment administration time was spent in silence.
• Participants described support providers as reassuring and consistently available, while remaining largely outside their conscious awareness during treatment.
• Support strategies encouraged patients to maintain an inward focus and independently navigate the psychedelic experience.
• Verbal interactions were brief and non-directive, emphasizing reassurance, validation, breath awareness, and physical presence instead of therapeutic dialogue or interpretation.

Compass noted that support providers across its clinical trials undergo standardized training and mentoring using a manualized framework informed by historical clinical experience and regulatory guidance. The approach promotes consistency while maintaining participant safety and data integrity.

Clinical Interpretation of the Findings

Dr. Guy Goodwin, Chief Medical Officer of Compass Pathways, said the findings reinforce that the monitoring and support incorporated into COMP360 clinical studies primarily safeguard participants rather than provide psychotherapy. He noted that patients consistently value the reassuring presence of trained support providers, while the therapeutic experience remains self-directed.

According to Goodwin, the analysis strengthens the interpretation that the rapid and durable symptom improvements previously observed in the open-label Phase 2 PTSD study were attributable to the psilocybin treatment itself rather than psychotherapeutic intervention.

Clinical Development and Regulatory Implications

The publication adds mechanistic evidence supporting Compass Pathways’ clinical development strategy for COMP360 across PTSD and treatment-resistant depression. By distinguishing supportive monitoring from psychotherapy, the findings may help clarify future clinical trial design and regulatory discussions surrounding psychedelic-assisted treatments. The company continues to advance COMP360 through ongoing clinical development while expanding the evidence base supporting its therapeutic potential in serious mental health disorders.

Reference

Compass Pathways – Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherap